NCT04080648View on ClinicalTrials.gov

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Psoriasis Vulgaris
Interventions
PROCEDURE

Venapuncture

Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of guselkumab.

OTHER

Patient questionnaires

The study participant will complete the dermatology quality of life index (DLQI) and EQ-5D-5L questionnaire at each study visit

Trial Locations (7)

3000

University Hospital, Leuven

8000

AZ Sint-Jan, Bruges

8820

AZ Delta Rembert, Torhout

9000

AZ Maria Middelares, Ghent

AZ Sint-Lucas, Ghent

University Hospital Ghent, Ghent

9990

Private practice Dermatology, Maldegem

All Listed Sponsors
collaborator

KU Leuven

OTHER

collaborator

University Ghent

OTHER

lead

University Hospital, Ghent

OTHER

NCT04080648 - Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients | Biotech Hunter | Biotech Hunter